- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02232555
Study to Evaluate the Efficacy of Duloxetine in Outpatients With Major Depressive Disorder and Pain
September 4, 2014 updated by: Boehringer Ingelheim
A Ten-week, Randomized, Double-blind Study Evaluating the Efficacy of Duloxetine 60 mg Once Daily Versus Placebo in Outpatients With Major Depressive Disorder and Pain (EU-Pain Enriched Study)
The purpose of this study was to investigate the efficacy of duloxetine versus placebo on pain in outpatients with major depressive disorder (MDD): change in Brief Pain Inventory Short Form (BPI-SF) 24-hour average pain score from baseline over the 8 weeks of treatment
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment
327
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female outpatients who meet the criteria for MDD according to the Diagnostic and Statistic Manual of mental disorders, 4th edition (DSM-IV) criteria and confirmed by Mini International Neuropsychiatric Interview (MINI)
- Montgomery-Asberg Depression Rating Scale (MADRS) score ≥20 at screening and baseline (Visits 1 and 2)
- Patients must have had at least one previous episode of depression in their medical history
- Painful physical symptoms (PPS) with a score ≥ 3 on the BPI-SF scale for average pain at screening and baseline
- Patient aged 18 years or older at the screening visit
- CGI-Severity score ≥ 4 at Visits 1 and 2
- Patients willing and able to comply with the scheduled visits, tests and procedures required by the protocol
- Written informed consent obtained at the screening visit, in accordance with Good clinical practice (GCP) and local regulatory requirements, prior to any study procedure
Exclusion Criteria:
Neuro-psychiatric exclusions
- Lack of response of the current episode to 2 or more adequate courses of antidepressant therapy given at a clinically appropriate dose and for a sufficient length of time in the judgement of the investigator
- Any anxiety disorder as a primary diagnosis within the past 6 months (including panic disorder, obsessive-compulsive disorder, posttraumatic stress disorder, generalized anxiety disorder, and social phobia). Note: Specific phobias (i.e. agoraphobia, arachnophobia, etc.) will be allowed
- Any diagnosis of bipolar disorder, schizophrenia, or other psychotic disorders
- Presence of an Axis II disorder which, in the judgement of the investigator, would interfere with compliance with the study protocol
- History of serious suicide attempt or patient judged to be at serious suicidal risk in the opinion of the investigator and / or score > 2 for question 10 (suicide) of the MADRS
- History of drug dependence, including alcohol or benzodiazepines, according to DSM-IV, in the previous year
- Positive urine screen for drug abuse (cannabis, benzodiazepines, barbiturates, opiates, cocaine, amphetamines)
Other medical exclusions
- Patients requiring continuous treatment with analgesics (> step 2 WHO definition) because of chronic pain (> 6 months)
- Patients with organic pain syndromes
- Epilepsy or history of seizure disorder or of a treatment with anticonvulsant medication for epilepsy or seizures
- Patients with a known diagnosis of raised intraocular pressure or at risk of acute narrow-angle glaucoma
- Known diagnosis of congenital galactosaemia, glucose or galactose malabsorption syndrome, or lactose deficiency
- Patients with severely impaired renal function, defined by a creatinine clearance < 30 mL/min (creatinine clearance was calculated by the central laboratory from the screening safety laboratory test
- Acute liver injury (such as hepatitis) or severe (Child-Pugh Class C) cirrhosis
- Abnormal initial ECG findings according to investigator's judgement
- Serious medical illness or clinically significant laboratory abnormalities which, in the judgement of the investigator, are likely to require medication/ intervention or hospitalization during the course of the study
- Women of childbearing potential not using a medically accepted means of contraception when engaging in sexual intercourse (e.g. intrauterine device, oral contraceptive, contraceptive patch, implant, or barrier devices)
- Women who are pregnant or breast-feeding
Pharmacological and other exclusions
- Participation in another clinical trial within 30 days prior to screening (Visit 1)
- Patients who have previously completed or withdrawn from this or any other study investigating duloxetine or have previously been treated with duloxetine
- Treatment with a monoamine oxidase inhibitor (MAOI) within 14 days prior to Visit 2 or potential need to use a MAOI within 5 days after discontinuation of study drug
- Treatment with fluoxetine within 28 days prior to Visit 2
Treatment with any of excluded medications (listed in Protocol) within 7 days prior to Visit 2
- (excepted MAOI within 14 days and fluoxetine within 28 days)
- Frequent and/or severe allergic reactions with multiple medications. Known hypersensitivity to duloxetine or any of the inactive ingredients
- Electro-convulsive Therapy (ECT) or Transcranial Magnetic Stimulation (TMS) within one year prior to screening
- Initiation or discontinuation of depression-oriented psychotherapeutic treatment (e.g. behavioural therapy, psychoanalytic therapy, cognitive therapy etc.) within 6 weeks prior to screening visit or planned use of such treatment at any time during the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo
|
|
EXPERIMENTAL: Duloxetine
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change of 24-hour average pain rated on Brief Pain Inventory-Short Form (BPI-SF) score
Time Frame: Up to 8 weeks after drug administration
|
Up to 8 weeks after drug administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Montgomery-Asberg Depression Rating Scale (MADRS) total score
Time Frame: Up to 8 weeks after drug administration
|
Up to 8 weeks after drug administration
|
|
Time to sustained clinical response for Painful Physical Symptoms (PPS) according BPI-SF score
Time Frame: Up to 8 weeks after drug administration
|
as defined by 30% reduction from baseline in question 5 (average pain) of the BPI-SF score
|
Up to 8 weeks after drug administration
|
Change of patient symptoms rated on Symptom Checklist 90 Revised (SCL-90-R) scale
Time Frame: Up to 8 weeks after drug administration
|
Up to 8 weeks after drug administration
|
|
Patients Global Impression (PGI) rated on PGI-improvement scale
Time Frame: Up to 8 weeks after drug administration
|
Up to 8 weeks after drug administration
|
|
Clinical Global Impressions (CGIs) by investigator rated on CGI-severity score
Time Frame: Up to 8 weeks after drug administration
|
Up to 8 weeks after drug administration
|
|
Clinical Global Impressions (CGIs) by investigator rated on CGI-improvement scale
Time Frame: Up to 8 weeks after drug administration
|
Up to 8 weeks after drug administration
|
|
Time to sustained clinical response for overall depression symptoms
Time Frame: Up to 8 weeks after drug administration
|
as defined by a 50% reduction from baseline in MADRS score
|
Up to 8 weeks after drug administration
|
Number of patients with adverse events
Time Frame: Up to 8 weeks after drug administration
|
Up to 8 weeks after drug administration
|
|
Number of patients withdrawing due to adverse event
Time Frame: Up to 8 weeks after drug administration
|
Up to 8 weeks after drug administration
|
|
Number of patients with clinical significant findings in vital signs
Time Frame: Up to 8 weeks after drug administration
|
blood pressure, pulse rate
|
Up to 8 weeks after drug administration
|
Number of patients with clinical significant findings in weight
Time Frame: Up to 8 weeks after drug administration
|
Up to 8 weeks after drug administration
|
|
Number of patients with clinical significant findings in laboratory values
Time Frame: Up to 8 weeks after drug administration
|
Up to 8 weeks after drug administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2005
Primary Completion (ACTUAL)
May 1, 2006
Study Registration Dates
First Submitted
September 4, 2014
First Submitted That Met QC Criteria
September 4, 2014
First Posted (ESTIMATE)
September 5, 2014
Study Record Updates
Last Update Posted (ESTIMATE)
September 5, 2014
Last Update Submitted That Met QC Criteria
September 4, 2014
Last Verified
August 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Mood Disorders
- Depression
- Depressive Disorder
- Depressive Disorder, Major
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Antidepressive Agents
- Dopamine Agents
- Serotonin and Noradrenaline Reuptake Inhibitors
- Duloxetine Hydrochloride
Other Study ID Numbers
- 1208.10
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depressive Disorder, Major
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States